Piacente et al. demonstrated that NAPRT-proficient ovarian and pancreatic cancers are resistant to FK866, whereas NAPRT downregulation through gene silencing or chemical inhibition with 2-hydroxynicotinic acid (2-HNA) sensitized tumor cells to NAMPT inhibitors both in vitro and in vivo [25]. This evidence concerns the gene NAMPT and neoplasm.